M A R C Y R L

Marcyrl Import & Export
Company” established

First manufacturing facility.

Delivering products under
license with MNCs.

Production facility expansion with the addition of new product

Establishment of the hormonal facility (sterile injectables), the first of its kind in Egypt.

First in Egypt to produce and launch Virus C products, allowing Marcyrl to penetrate the growing tender market.

Establishment of the respiratory facility, the first of its kind in Egypt.

New Land, Plan for a new facility for expansion.

Entry of institutional investors - Development Partners International (DPI) and Amethis, Africa-focused PE funds with strong pharma exposure

Pioneering Breakthroughs:

Marcyrl's Mission to Transform
Healthcare Across Continents

At Marcyrl, our mission is to be a beacon of hope and healing across continents, pioneering breakthroughs in pharmaceutical innovation and accessibility. Since our inception in 1996 as Marcyrl Import & Export Company, we have evolved into one of the Leading Global Pharmaceutical Companies, steadfastly committed to delivering cost-effective critical solutions to healthcare practitioners and their patients across Africa and the GCC region. Our journey is marked by milestones of excellence and dedication, from the establishment of our ﬁrst manufacturing facility in 2003 under-license agreements with multinational corporations to the expansion of our production capabilities in 2013, catalyzing a new era of growth and innovation.

Charting a Path Towards Excellence:

Marcyrl's Vision for a Brighter
Future in Healthcare

Our vision at Marcyrl is to redeﬁne the landscape of healthcare by continuously pushing the boundaries of possibility and compassion. As we embark on a journey towards a new facility for expansion in 2021, we envision a future where our EU GMP–certiﬁed manufacturing facilities serve as bastions of hope, producing innovative diversiﬁed specialty care treatments that address critical healthcare needs in different therapeutic areas, With a strong presence covering Africa and the GCC, we aspire to lead the way in delivering cost-effective critical solutions to healthcare practitioners to deliver optimal care to their patients, fostering healthier communities and a brighter tomorrow.

Excellence

We uphold a steadfast commitment to excellence in everything we do, striving for perfection in our research, development, manufacturing, and distribution processes to ensure the highest quality and efficacy of our products.

Innovation and Quality: "We are dedicated to pioneering innovations and maintaining unparalleled quality in all our endeavors, from research and development to manufacturing and distribution, ensuring superior efficacy in our products."

Excellence and Integrity: "Our unwavering commitment to excellence and integrity drives us to achieve perfection in our research, development, manufacturing, and distribution, delivering products of the highest quality and effectiveness."

Patient-Centered Care: "We strive for perfection in every aspect of our work, from research and development to manufacturing and distribution, ensuring our products meet the highest standards of quality and efficacy for the well-being of our patients."

Sustainability and Responsibility: "Our steadfast commitment to sustainability and responsibility guides us in every process, from research and development to manufacturing and distribution, ensuring the highest quality and efficacy of our products while caring for the environment and society."

Collaboration and Progress: "We uphold a steadfast commitment to collaboration and progress, striving for excellence in research, development, manufacturing, and distribution processes to ensure our products meet the highest standards of quality and efficacy."

The Board Members

Marcyrl has visionary minds behind our mission. Our board members bring expertise, passion, and leadership
to guide us toward a brighter future. Together, we lead the way for innovation

Mr Farid Habib
Founders

Dr Saad Ibrahim
Founders

Dr Wagdy Mounir
Founders

Dr George Saad
Managing directors and board members

Dr Micheal Wagdy
Managing directors and board members

Dr Mina Wagdy
Managing directors and board members

Investors

Impressed by Marcyrl’s solid performance and strong management team, Africa- focused private
equity funds DPI and Amethis announced their investment in Marcyrl in 2023

Amethis is an investment fund manager dedicated to Africa and Europe, with an investment capacity exceeding €1.1bn. Amethis brings growth capital to promising midcap champions in a diversity of sectors throughout the African and European continents.As an active shareholder, Amethis offers key support and expertise through its international network, its opportunities of external growth, and its value-added governance.

DPI was founded in 2007 on the vision of building a premier investment firm with excellence at its core. We wanted to back exceptional businesses to allow African entrepreneurs and CEOs to achieve their ambitions, while striving to deliver top-quartile returns and positive impact for Africa.

Why partner with Marcyrl

A Wide portfolio including a niche
in hormonal and respiratory

325 SKUs mainly in chronic disease areas; 300 SKUs in the pipeline A portfolio spanning 15 TAs, in particular female health/fertility, cardiovascular, urology, neuroscience, gastroenterology, etc. Niche in novel, high-complexity products (in particular hormonal, respiratory)

Why partner with Marcyrl

Wide portfolio including niche
in hormonal and respiratory products

Top-notch R&D and manufacturing capabilities with EU GMP-certified facilities Cost competitiveness built on world-class procurement and lean operations – Track record of effective cost containment despite sharp currency devaluation 2017-2021; Leadership in the tender market (11% of sales in 2021)

Why partner with Marcyrl

Track record of registering and
commercializing in export markets

Existing export footprint
in 23 countries outside of Egypt
107 successful registrations in export markets,
106 products under registration

Why partner with Marcyrl

Strong management team, backed by
leading institutional investors

Experienced management with diverse expertise
Entry of DPI and Amethis in 2023
- combined AUM of USD 3.6 billion,
Africa focused with strong pharma exposure